Now showing items 1-20 of 631

    • 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. 

      Cameron, D; Piccart-Gebhart, MJ; Gelber, RD; Procter, M; Goldhirsch, A; de Azambuja, E; Castro, G; Untch, M; Smith, I; Gianni, L; Baselga, J; Al-Sakaff, N; Lauer, S; McFadden, E; Leyland-Jones, B; Bell, R; Dowsett, M; Jackisch, C; Herceptin Adjuvant (HERA) Trial Study Team (2017-03)
      <h4>Background</h4>Clinical trials have shown that trastuzumab, a recombinant monoclonal antibody against HER2 receptor, significantly improves overall survival and disease-free survival in women with HER2-positive early ...
    • 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. 

      Pan, H; Gray, R; Braybrooke, J; Davies, C; Taylor, C; McGale, P; Peto, R; Pritchard, KI; Bergh, J; Dowsett, M; Hayes, DF; EBCTCG (2017-11)
      <h4>Background</h4>The administration of endocrine therapy for 5 years substantially reduces recurrence rates during and after treatment in women with early-stage, estrogen-receptor (ER)-positive breast cancer. Extending ...
    • 3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer. 

      Peck, B; Bland, P; Mavrommati, I; Muirhead, G; Cottom, H; Wai, PT; Maguire, SL; Barker, HE; Morrison, E; Kriplani, D; Yu, L; Gibson, A; Falgari, G; Brennan, K; Farnie, G; Buus, R; Marlow, R; Novo, D; Knight, E; Guppy, N; Kolarevic, D; Susnjar, S; Milijic, NM; Naidoo, K; Gazinska, P; Roxanis, I; Pancholi, S; Martin, L-A; Holgersen, EM; Cheang, MCU; Noor, F; Postel-Vinay, S; Quinn, G; McDade, S; Krasny, L; Huang, P; Daley, F; Wallberg, F; Choudhary, JS; Haider, S; Tutt, AN; Natrajan, R (2021-01-28)
      Triple-negative breast cancers (TNBC) are resistant to standard-of-care chemotherapy and lack known targetable driver gene alterations. Identification of novel drivers could aid the discovery of new treatment strategies ...
    • 90 YEARS OF PROGESTERONE: Progesterone receptor signaling in the normal breast and its implications for cancer. 

      Brisken, C; Scabia, V (2020-07)
      Progesterone is considered as the pregnancy hormone and acts on many different target tissues. Progesterone receptor (PR) signaling is important for normal development and the physiologic function of the breast and impinges ...
    • ABC-transporter upregulation mediates resistance to the CDK7 inhibitors THZ1 and ICEC0942. 

      Sava, GP; Fan, H; Fisher, RA; Lusvarghi, S; Pancholi, S; Ambudkar, SV; Martin, L-A; Charles Coombes, R; Buluwela, L; Ali, S (2020-01)
      The CDK7 inhibitors (CDK7i) ICEC0942 and THZ1, are promising new cancer therapeutics. Resistance to targeted drugs frequently compromises cancer treatment. We sought to identify mechanisms by which cancer cells may become ...
    • Abiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phase II Cancer of the Ovary Abiraterone (CORAL) trial (CRUK-A16037) 

      Banerjee, S; Tovey, H; Bowen, R; Folkerd, E; Kilburn, L; McLachlan, J; Hall, M; Tunariu, N; Attygalle, A; Lima, JPDSN; Perry, S; Chatfield, P; Hills, M; Kaye, S; Attard, G; Dowsett, M; Bliss, JM (SAGE PUBLICATIONS LTD, 2020-12-01)
    • Abiraterone shows alternate activity in models of endocrine resistant and sensitive disease 

      Simigdala, N; Pancholi, S; Ribas, R; Folkerd, E; Liccardi, G; Nikitorowicz-Buniak, J; Johnston, SR; Dowsett, M; Martin, L
    • Abiraterone shows alternate activity in models of endocrine resistant and sensitive disease. 

      Simigdala, N; Pancholi, S; Ribas, R; Folkerd, E; Liccardi, G; Nikitorowicz-Buniak, J; Johnston, SR; Dowsett, M; Martin, L-A (2018-08)
      <h4>Background</h4>Resistance to endocrine therapy remains a major clinical problem in the treatment of oestrogen-receptor positive (ER+) breast cancer. Studies show androgen-receptor (AR) remains present in 80-90% of ...
    • Accountability in the NHS: the impact on cancer care. 

      Macklin-Doherty, A (2018-01)
      Accountability of service delivery is becoming increasingly complex and never has this been more apparent than in the field of Oncology. Cancer care has an unrivalled level of complexity not only in the heterogeneity of ...
    • Accuracy of classification of invasive lobular carcinoma on needle core biopsy of the breast. 

      Naidoo, K; Beardsley, B; Carder, PJ; Deb, R; Fish, D; Girling, A; Hales, S; Howe, M; Wastall, LM; Lane, S; Lee, AHS; Philippidou, M; Quinn, C; Stephenson, T; Pinder, SE (2016-12)
      Although the UK National Institute for Health and Care Excellence guidelines recommend that in patients with biopsy-proven invasive lobular carcinoma (ILC), preoperative MRI scan is considered, the accuracy of diagnosis ...
    • Accurate clinical detection of exon copy number variants in a targeted NGS panel using DECoN. 

      Fowler, A; Mahamdallie, S; Ruark, E; Seal, S; Ramsay, E; Clarke, M; Uddin, I; Wylie, H; Strydom, A; Lunter, G; Rahman, N (2016-11-25)
      <b>Background:</b> Targeted next generation sequencing (NGS) panels are increasingly being used in clinical genomics to increase capacity, throughput and affordability of gene testing. Identifying whole exon deletions or ...
    • Actin-myosin-based contraction is responsible for apoptotic nuclear disintegration. 

      Croft, DR; Coleman, ML; Li, S; Robertson, D; Sullivan, T; Stewart, CL; Olson, MF (2005-01)
      Membrane blebbing during the apoptotic execution phase results from caspase-mediated cleavage and activation of ROCK I. Here, we show that ROCK activity, myosin light chain (MLC) phosphorylation, MLC ATPase activity, and ...
    • Adapting care for older cancer patients during the COVID-19 pandemic: Recommendations from the International Society of Geriatric Oncology (SIOG) COVID-19 Working Group. 

      Battisti, NML; Mislang, AR; Cooper, L; O'Donovan, A; Audisio, RA; Cheung, K-L; Sarrió, RG; Stauder, R; Soto-Perez-de-Celis, E; Jaklitsch, M; Williams, GR; O'Hanlon, S; Alam, M; Cairo, C; Colloca, G; Gil, LA; Sattar, S; Kantilal, K; Russo, C; Lichtman, SM; Brain, E; Kanesvaran, R; Wildiers, H (2020-11)
      The COVID-19 pandemic poses a barrier to equal and evidence-based management of cancer in older adults. The International Society of Geriatric Oncology (SIOG) formed a panel of experts to develop consensus recommendations ...
    • Adaptive immunity to SARS-CoV-2 in cancer patients: The CAPTURE study. 

      Au, L; Fendler, A; Boos, LA; Byrnes, F; Shepherd, S; Nicholson, E; Kumar, S; Yousaf, N; Wilkinson, K; Swerdlow, A; Harvey, R; Kassiotis, G; Wilkinson, R; Larkin, J; Turajlic, S (AMER ASSOC CANCER RESEARCH, 2020-03-01)
    • Adult weight change and premenopausal breast cancer risk: A prospective pooled analysis of data from 628,463 women. 

      Schoemaker, MJ; Nichols, HB; Wright, LB; Brook, MN; Jones, ME; O'Brien, KM; Adami, H-O; Baglietto, L; Bernstein, L; Bertrand, KA; Boutron-Ruault, M-C; Chen, Y; Connor, AE; Dossus, L; Eliassen, AH; Giles, GG; Gram, IT; Hankinson, SE; Kaaks, R; Key, TJ; Kirsh, VA; Kitahara, CM; Larsson, SC; Linet, M; Ma, H; Milne, RL; Ozasa, K; Palmer, JR; Riboli, E; Rohan, TE; Sacerdote, C; Sadakane, A; Sund, M; Tamimi, RM; Trichopoulou, A; Ursin, G; Visvanathan, K; Weiderpass, E; Willett, WC; Wolk, A; Zeleniuch-Jacquotte, A; Sandler, DP; Swerdlow, AJ (2020-09)
      Early-adulthood body size is strongly inversely associated with risk of premenopausal breast cancer. It is unclear whether subsequent changes in weight affect risk. We pooled individual-level data from 17 prospective studies ...
    • Advances and challenges in targeting FGFR signalling in cancer. 

      Babina, IS; Turner, NC (2017-05)
      Fibroblast growth factors (FGFs) and their receptors (FGFRs) regulate numerous cellular processes. Deregulation of FGFR signalling is observed in a subset of many cancers, making activated FGFRs a highly promising potential ...
    • Advances in the treatment of advanced oestrogen-receptor-positive breast cancer. 

      Turner, NC; Neven, P; Loibl, S; Andre, F (2017-06)
      Oestrogen-receptor-positive breast cancer is the most common subtype of breast cancer. Endocrine therapies that target the dependence of this subtype on the oestrogen receptor have substantial activity, yet the development ...
    • Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers. 

      Schmidt, MK; Hogervorst, F; van Hien, R; Cornelissen, S; Broeks, A; Adank, MA; Meijers, H; Waisfisz, Q; Hollestelle, A; Schutte, M; van den Ouweland, A; Hooning, M; Andrulis, IL; Anton-Culver, H; Antonenkova, NN; Antoniou, AC; Arndt, V; Bermisheva, M; Bogdanova, NV; Bolla, MK; Brauch, H; Brenner, H; Brüning, T; Burwinkel, B; Chang-Claude, J; Chenevix-Trench, G; Couch, FJ; Cox, A; Cross, SS; Czene, K; Dunning, AM; Fasching, PA; Figueroa, J; Fletcher, O; Flyger, H; Galle, E; García-Closas, M; Giles, GG; Haeberle, L; Hall, P; Hillemanns, P; Hopper, JL; Jakubowska, A; John, EM; Jones, M; Khusnutdinova, E; Knight, JA; Kosma, V-M; Kristensen, V; Lee, A; Lindblom, A; Lubinski, J; Mannermaa, A; Margolin, S; Meindl, A; Milne, RL; Muranen, TA; Newcomb, PA; Offit, K; Park-Simon, T-W; Peto, J; Pharoah, PDP; Robson, M; Rudolph, A; Sawyer, EJ; Schmutzler, RK; Seynaeve, C; Soens, J; Southey, MC; Spurdle, AB; Surowy, H; Swerdlow, A; Tollenaar, RAEM; Tomlinson, I; Trentham-Dietz, A; Vachon, C; Wang, Q; Whittemore, AS; Ziogas, A; van der Kolk, L; Nevanlinna, H; Dörk, T; Bojesen, S; Easton, DF (2016-08)
      <h4>Purpose</h4>CHEK2*1100delC is a well-established breast cancer risk variant that is most prevalent in European populations; however, there are limited data on risk of breast cancer by age and tumor subtype, which limits ...
    • Analgesic Use and Ovarian Cancer Risk: An Analysis in the Ovarian Cancer Cohort Consortium. 

      Trabert, B; Poole, EM; White, E; Visvanathan, K; Adami, H-O; Anderson, GL; Brasky, TM; Brinton, LA; Fortner, RT; Gaudet, M; Hartge, P; Hoffman-Bolton, J; Jones, M; Lacey, JV; Larsson, SC; Mackenzie, GG; Schouten, LJ; Sandler, DP; O'Brien, K; Patel, AV; Peters, U; Prizment, A; Robien, K; Setiawan, VW; Swerdlow, A; van den Brandt, PA; Weiderpass, E; Wilkens, LR; Wolk, A; Wentzensen, N; Tworoger, SS; Ovarian Cancer Cohort Consortium (OC3) (2019-02)
      BACKGROUND:Aspirin use is associated with reduced risk of several cancers. A pooled analysis of 12 case-control studies showed a 10% decrease in ovarian cancer risk with regular aspirin use, which was stronger for daily ...
    • Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of <i>BRCA2</i> Reversion Mutations Associated with Resistance to PARP Inhibitors. 

      Quigley, D; Alumkal, JJ; Wyatt, AW; Kothari, V; Foye, A; Lloyd, P; Aggarwal, R; Kim, W; Lu, E; Schwartzman, J; Beja, K; Annala, M; Das, R; Diolaiti, M; Pritchard, C; Thomas, G; Tomlins, S; Knudsen, K; Lord, CJ; Ryan, C; Youngren, J; Beer, TM; Ashworth, A; Small, EJ; Feng, FY (2017-09)
      Approximately 20% of metastatic prostate cancers harbor mutations in genes required for DNA repair by homologous recombination repair (HRR) such as <i>BRCA2</i> HRR defects confer synthetic lethality to PARP inhibitors ...